MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Pulmonology (Drugs, Pharmaceuticals, Biotechnology & Biosimilars)
Galecto Biotech, Inc. (Nasdaq: GLTO)
Organization & Developments: Galecto Biotech
Parents
Galecto Biotech, Inc. (Nasdaq: GLTO)
Children
2020: Galecto and PharmAkea merge to create strong clinical-stage company developing first-in-class therapeutics in fibrosis and cancer – Galecto, Inc.
Galecto Inc. is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation and cancer
Galecto, Inc. (NASDAQ: GLTO) is a small-cap clinical-stage biotechnology company focused on treatments for fibrosis and cancer
Leading developer of galectin modulators for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and cancer
The company’s products target galectins or galactoside binding lectins, which are a group of proteins shown to be involved in many disease processes
Jumps
Finance & Acquisitions: Galecto Biotech
Key People: Galecto Biotech